Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
37
NBY Quote, Financials, Valuation and Earnings
Last price:
$1.08
Seasonality move
:
-8.25%
Day range:
$1.00 - $1.07
52-week range:
$0.46 - $4.44
Dividend yield:
0%
P/E ratio:
1.78x
P/S ratio:
2.06x
P/B ratio:
1.50x
Volume:
43.7K
Avg. volume:
134.4K
1-year change:
85.31%
Market cap:
$133.6M
Revenue:
$9.8M
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-- | -$0.32 | -100% | -13.23% | $5.00 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.06 | $0.85 | $133.6M | 1.78x | $0.80 | 0% | 2.06x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.45 | $5.00 | $45.2M | -- | $0.00 | 0% | 502.60x |
|
NNVC
NanoViricides, Inc.
|
$1.11 | $7.00 | $20M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $711.4K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
7.66% | -2.165 | 2.29% | 7.81x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-$116K | -$5.7M | -126.64% | -133.63% | -6324.44% | -$6.3M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
NovaBay Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns NBY or ATNM?
Actinium Pharmaceuticals, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of -5701.11%. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M ATNMActinium Pharmaceuticals, Inc.-128.89% -$0.16 $14.9M -
What do Analysts Say About NBY or ATNM?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -19.81%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 244.83%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 ATNMActinium Pharmaceuticals, Inc.3 1 0 -
Is NBY or ATNM More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.367, suggesting its less volatile than the S&P 500 by 136.662%.
-
Which is a Better Dividend Stock NBY or ATNM?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or ATNM?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.78x while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 2.06x versus 502.60x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M ATNMActinium Pharmaceuticals, Inc.502.60x -- $90K -$5.1M
-
Which has Higher Returns NBY or NNVC?
NanoViricides, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About NBY or NNVC?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -19.81%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 530.63%. Given that NanoViricides, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is NBY or NNVC More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock NBY or NNVC?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or NNVC?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than NanoViricides, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.78x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 2.06x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns NBY or OGEN?
Oragenics, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About NBY or OGEN?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -19.81%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 131.36%. Given that Oragenics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is NBY or OGEN More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock NBY or OGEN?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or OGEN?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Oragenics, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.78x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 2.06x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns NBY or PTN?
Palatin Technologies has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About NBY or PTN?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -19.81%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is NBY or PTN More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock NBY or PTN?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or PTN?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Palatin Technologies quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Palatin Technologies's net income of --. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.78x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 2.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns NBY or TOVX?
Theriva Biologics, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About NBY or TOVX?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -19.81%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is NBY or TOVX More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock NBY or TOVX?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or TOVX?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.78x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 2.06x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
